[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654424":3},{"organization":4,"outcomesModule":7,"designInfo":60,"detailedDescription":63,"studyPopulation":64,"armGroups":65,"interventions":59,"overallOfficials":59,"centralContacts":69,"locations":76,"responsibleParty":129,"collaborators":59,"id":131,"slug":132,"hasResults":133,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":133,"sex":139,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":59,"studyType":145,"phases":59,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":90,"whyStopped":59,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":43,"otherOutcomes":59},[9,13,16,20,23,26,29,32,35,38,41],{"measure":10,"description":11,"timeFrame":12},"Distribution of GC\u002FGEJ cancer types","Percentage of GC\u002FGEJ cancer types (adenocarcinoma, squamous cell carcinoma, other).","Measured at baseline, during patients 1st visit.",{"measure":14,"description":15,"timeFrame":12},"Clinicopathological characteristics of patients with histologically confirmed stage II to IVB gastric\u002FGEJ cancer.","Patient and disease characteristics at diagnosis for patients with histologically confirmed stage II to IVB GC\u002FGEJ adenocarcinoma.",{"measure":17,"description":18,"timeFrame":19},"To capture the current treatment strategies of patients with stage II to IVB gastric\u002FGEJ adenocarcinoma.","To describe current treatment modalities (surgery, systemic therapy, radiotherapy, chemoradiation (CRT) and palliative care) applied in the resectable (Stages II-IVA) and advanced\u002Fmetastatic (Stage IVB) settings, presented as types","Up to 18 months ± 30 days (through study completion)",{"measure":21,"description":22,"timeFrame":19},"To capture the current treatment strategies of patients with stage II to IVB gastric\u002FGEJ adenocarcinoma, measured as frequencies per stage","To describe current treatment modalities (surgery, systemic therapy, radiotherapy, chemoradiation (CRT) and palliative care) applied in the resectable (Stages II-IVA) and advanced\u002Fmetastatic (Stage IVB) settings, presented as frequencies per stage.",{"measure":24,"description":25,"timeFrame":19},"Estimation of key time intervals, measured by time (months) from diagnosis to neoadjuvant or perioperative treatment and\u002For surgery (if applicable)","To capture the current treatment strategies of patients with stage II to IVB gastric\u002FGEJ adenocarcinoma by estimating key time intervals, including time (months) from diagnosis to neoadjuvant or perioperative treatment and\u002For surgery (if applicable).",{"measure":27,"description":28,"timeFrame":19},"Estimation of key time intervals, measured by time (months) from surgery to adjuvant systemic treatment (for Stage II-IVA)","To capture the current treatment strategies of patients with stage II to IVB gastric\u002FGEJ adenocarcinoma by estimation of key time intervals, including time (months) from surgery to adjuvant systemic treatment (for Stage II-IVA)",{"measure":30,"description":31,"timeFrame":19},"Estimation of key time intervals, measured by time (months) from first to second-line.","To capture the current treatment strategies of patients with stage II to IVB gastric\u002FGEJ adenocarcinoma by estimating key time intervals, including time (months) from first to second-line.",{"measure":33,"description":34,"timeFrame":19},"Estimation of key time intervals, measured by time (months) from second-line to third-line systemic treatment (for Stage IVB).","To capture the current treatment strategies of patients with stage II to IVB gastric\u002FGEJ adenocarcinoma by estimating key time intervals, including time (months) from second-line to third-line systemic treatment (for Stage IVB).",{"measure":36,"description":37,"timeFrame":19},"Duration of each systemic treatment line (overall and by type: chemotherapy, targeted therapy\u002Fimmunotherapy; up to 3rd line)","To capture the current treatment strategies of patients with stage II to IVB gastric\u002FGEJ adenocarcinoma by estimating the duration of each systemic treatment line (overall and by type: chemotherapy, targeted therapy\u002Fimmunotherapy; up to 3rd line)",{"measure":39,"description":40,"timeFrame":19},"Description of dosing schemes","To capture the current treatment strategies of patients with stage II to IVB gastric\u002FGEJ adenocarcinoma by describing dosing schemes.",{"measure":17,"description":42,"timeFrame":19},"To describe treatment sequences.",[44,47,50,53,56],{"measure":45,"description":46,"timeFrame":19},"Pathologic complete response (pCR) rate","The proportion of patients with stage II-IVA gastric\u002FGEJ adenocarcinoma with no viable tumor cells, including lymph nodes, in the resected gastric specimen after completion of neoadjuvant therapy and surgery.",{"measure":48,"description":49,"timeFrame":19},"Description of types of biomarkers tested at diagnosis, by disease stage (II-IVA, IVB).","To evaluate current biomarker testing strategies and patterns among patients with stage II to IVB gastric\u002FGEJ adenocarcinoma, based on information about types of biomarkers tested at diagnosis, by disease stage (II-IVA, IVB).",{"measure":51,"description":52,"timeFrame":19},"Percentage of patients tested for biomarkers.","To evaluate current biomarker testing strategies and patterns among patients with stage II to IVB gastric\u002FGEJ adenocarcinoma, based on percentage of patients tested for biomarkers.",{"measure":54,"description":55,"timeFrame":19},"Percentage of positive results by biomarker type.","To evaluate current biomarker testing strategies and patterns among patients with stage II to IVB gastric\u002FGEJ adenocarcinoma, based on percentage of positive results by biomarker type.",{"measure":57,"description":58,"timeFrame":19},"Time from diagnosis to biomarker results captured during biomarkers testing by disease stage (II-IVA, IVB).","To evaluate current biomarker testing strategies and patterns among patients with stage II to IVB gastric\u002FGEJ adenocarcinoma, based on information on biomarkers testing by disease stage (II-IVA, IVB), including time from diagnosis to biomarker results.",null,{"allocation":59,"interventionModel":59,"interventionModelDescription":59,"primaryPurpose":59,"observationalModel":61,"timePerspective":62,"maskingInfo":59},"COHORT","CROSS_SECTIONAL","Patients may withdraw from the study at any time at their own request, or they may be withdrawn at any time at the discretion of the Investigator or AstraZeneca. In all cases, every reasonable effort should be made to document patient outcome, if applicable.","Approximately 300 adult patients with histologically confirmed, stage II to IVB gastric\u002FGEJ adenocarcinoma will be enrolled from 10-15 oncology clinics of large public and private hospitals, covering diverse geographic areas, in Greece.",[66],{"label":67,"type":59,"description":68,"interventionNames":59},"Patients with Stage II-IVB Gastric\u002FGEJ Adenocarcinoma","Adult patients with histologically confirmed, stage II to IVB gastric\u002FGEJ adenocarcinoma will be enrolled from 10-15 oncology clinics of large public and private hospitals, covering diverse geographic areas, in Greece. Eligible patients will have been diagnosed between June 1st, 2025 and the end of the recruitment period (Q3 2027). The study includes both retrospective and prospective components.",[70],{"name":71,"role":72,"phone":73,"phoneExt":74,"email":75},"AstraZeneca Clinical Study Information Center","CONTACT","877-240-9479","1","information.center@astrazeneca.com",[77,89,97,101,106,108,115,122],{"facility":78,"status":79,"city":80,"state":59,"zip":59,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":88,"contacts":59},"Research Site","NOT_YET_RECRUITING","Alexandroupoli","Greece","GR",{"type":84,"coordinates":85},"Point",[86,87],25.87644,40.84995,{"lat":87,"lon":86},{"facility":78,"status":90,"city":91,"state":59,"zip":59,"country":81,"countryCode":82,"cosmosGeoPoint":92,"geoPoint":96,"contacts":59},"RECRUITING","Athens",{"type":84,"coordinates":93},[94,95],23.72784,37.98376,{"lat":95,"lon":94},{"facility":78,"status":79,"city":91,"state":59,"zip":59,"country":81,"countryCode":82,"cosmosGeoPoint":98,"geoPoint":100,"contacts":59},{"type":84,"coordinates":99},[94,95],{"lat":95,"lon":94},{"facility":78,"status":102,"city":91,"state":59,"zip":59,"country":81,"countryCode":82,"cosmosGeoPoint":103,"geoPoint":105,"contacts":59},"WITHDRAWN",{"type":84,"coordinates":104},[94,95],{"lat":95,"lon":94},{"facility":78,"status":79,"city":107,"state":59,"zip":59,"country":81,"countryCode":82,"cosmosGeoPoint":59,"geoPoint":59,"contacts":59},"Crete",{"facility":78,"status":79,"city":109,"state":59,"zip":59,"country":81,"countryCode":82,"cosmosGeoPoint":110,"geoPoint":114,"contacts":59},"Ioannina",{"type":84,"coordinates":111},[112,113],20.85187,39.66341,{"lat":113,"lon":112},{"facility":78,"status":79,"city":116,"state":59,"zip":59,"country":81,"countryCode":82,"cosmosGeoPoint":117,"geoPoint":121,"contacts":59},"Pátrai",{"type":84,"coordinates":118},[119,120],21.73508,38.2462,{"lat":120,"lon":119},{"facility":78,"status":79,"city":123,"state":59,"zip":59,"country":81,"countryCode":82,"cosmosGeoPoint":124,"geoPoint":128,"contacts":59},"Thessaloniki",{"type":84,"coordinates":125},[126,127],22.93493,40.64072,{"lat":127,"lon":126},{"type":130,"investigatorFullName":59,"investigatorTitle":59,"investigatorAffiliation":59,"oldNameTitle":59,"oldOrganization":59},"SPONSOR","100654424","a-study-in-greece-observing-how-patients-with-stomach-and-esophageal-cancer-are-diagnosed-and-treated-in-everyday-medical-practice-100654424",false,"NCT07800754","A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treated in Everyday Medical Practice","Epidemiological Characteristics And Management Strategies Of Gastric\u002FGastrophaegal Junction Cancer Patients In Routine Clinical Practice: A Greek Multicenter Observational Study (The GRACE Study)","GRACE","Inclusion Criteria:\n\n* Patients aged ≥18 years upon gastric\u002FGEJ adenocarcinoma diagnosis.\n* Written signed and dated informed consent by the patient (or their legally acceptable representative, as applicable). For deceased patients on the date of study entry a waiver of consent must be approved by the Hospital EC\u002FIRB.\n* Patients diagnosed with histologically confirmed, stage II to IVB adenocarcinoma of gastric\u002FGEJ, between June 1st, 2025 and the end of the recruitment period (Q3 2027).\n\nExclusion Criteria:\n\n* Patients who participate or participated during the data collection period (prospective and retrospective) in any clinical investigation\u002Fclinical trial that includes interventions that fall outside the everyday clinical practice.\n* Patients who have participated in the design and\u002For the conduct of the study.\n* Patients with another primary malignancy within the last 5 years, for which systemic anticancer treatment is required after the diagnosis of gastric\u002FGEJ cancer.","ALL","18 Years","130 Years",{"count":143,"type":144},300,"ESTIMATED","OBSERVATIONAL","This is a retrospective-prospective observational, multicenter, single-country study aiming to describe the epidemiological characteristics and management strategies in patients with stage II-IVB gastric\u002FGEJ adenocarcinoma in routine clinical practice in Greece.",[148,149],"Gastric Cancer","Gastroesophageal Junction Cancer",[148,149,151,152,153,154,155,81],"Adenocarcinoma","Observational Study","Real-World Evidence","Epidemiology","Treatment Patterns","2026-10-07",{"date":158,"type":159},"2026-10-08","ACTUAL",{"date":161,"type":159},"2026-09-30",{"date":163,"type":144},"2027-12-31",{"name":5,"class":6},8]